Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.
Adult
Aged
Aged, 80 and over
Cluster Analysis
Diabetes Mellitus, Type 2
/ drug therapy
Female
Follow-Up Studies
France
Humans
Hyperglycemia
/ drug therapy
Hypoglycemic Agents
/ therapeutic use
Male
Medication Adherence
/ statistics & numerical data
Middle Aged
Patient Education as Topic
/ methods
Pharmacists
/ psychology
Physician-Patient Relations
Surveys and Questionnaires
Disease knowledge
Glucose control
Patient information
Pharmacist
Type 2 diabetes
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
13
03
2019
pubmed:
3
5
2019
medline:
1
5
2020
entrez:
4
5
2019
Statut:
ppublish
Résumé
Low-quality communication between patients and care providers and limited patient knowledge of the disease and the therapy are important factors associated with poor glycemic control in patients with type 2 diabetes. We conducted a multicenter study to determine whether structured and tailored information delivered by pharmacists to type 2 diabetic patients could improve patient treatment adherence, hemoglobin A1c (HbA1c) levels and knowledge about diabetes. One hundred seventy-four pharmacies were randomized to deliver an educational program on diet, drug treatment, disease and complications during three 30-min interviews over a 6-month period, or to provide no intervention, to type 2 diabetic patients treated with oral antidiabetic agents. Medication adherence was assessed by measuring the medication possession ratio and diabetes control by collecting HbA1c values. Levels of patient treatment self-management and disease knowledge were assessed using self-questionnaires. Three hundred seventy-seven patients were analyzed. The medication possession ratio, already very high at baseline in the intervention (94.8%) and control (92.3%) groups, did not vary significantly after 6 months with no difference between the two groups. Significant decreases in HbA1c were observed in both groups at 6 months (p < 0.001) and 12 months (p < 0.01), with significantly greater changes from baseline in the intervention group than in the control group at 6 months (- 0.5% vs. - 0.2%, p = 0.0047) and 12 months (- 0.6% vs. - 0.2%, p = 0.0057). Patients in the intervention group showed greater improvement in their ability to self-manage treatment (+ 4.86 vs. + 1.58, p = 0.0014) and in the extent of their knowledge about diabetes (+ 0.6 vs. + 0.2, p < 0.01) at 6 months versus baseline compared with the control group. Tailored information provided by the pharmacist to patients with type 2 diabetes did not significantly improve the already high adherence rates, but was associated with a significant decrease in HbA1c and an improvement of patient knowledge about diabetes. ISRCTN33776525. MSD France.
Identifiants
pubmed: 31049873
doi: 10.1007/s12325-019-00957-y
pii: 10.1007/s12325-019-00957-y
pmc: PMC6824455
doi:
Substances chimiques
Hypoglycemic Agents
0
Banques de données
ISRCTN
['ISRCTN33776525']
figshare
['10.6084/m9.figshare.7964879']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1291-1303Références
AIDS Patient Care STDS. 2014 Dec;28(12):622-7
pubmed: 25396706
Endocr Pract. 2016 Jan;22(1):84-113
pubmed: 26731084
Patient Prefer Adherence. 2016 Aug 16;10:1573-81
pubmed: 27574406
JAMA. 2006 Dec 6;296(21):2563-71
pubmed: 17101639
Behav Res Ther. 2004 Apr;42(4):409-22
pubmed: 14998735
J Manag Care Spec Pharm. 2016 May;22(5):493-515
pubmed: 27123912
Eur J Health Econ. 2018 Mar;19(2):189-201
pubmed: 28190188
Diabetes Care. 2017 Nov;40(11):1425-1432
pubmed: 28801473
Am J Manag Care. 2012 Apr;18(3 Suppl):S43-8
pubmed: 22558941
Saudi Pharm J. 2016 Jan;24(1):40-8
pubmed: 26903767
Diabetes Metab. 2013 May;39(3):250-7
pubmed: 23523643
Ann Pharmacother. 2004 Sep;38(9):1357-62
pubmed: 15238621
Patient Educ Couns. 2016 Jun;99(6):926-43
pubmed: 26658704
JAMA Dermatol. 2014 Aug;150(8):813-4
pubmed: 24898730
J Clin Pharm Ther. 2011 Oct;36(5):602-13
pubmed: 21143256
Clin Endocrinol (Oxf). 2014 Jan;80(1):47-56
pubmed: 23194193
BMC Health Serv Res. 2014 Nov 13;14:533
pubmed: 25391694
Diabetes Care. 2009 Jan;32(1):19-24
pubmed: 18852334
Ann Pharmacother. 2011 Feb;45(2):145-53
pubmed: 21304027
Diabetes Obes Metab. 2018 Jan;20(1):185-194
pubmed: 28730750
Chronic Illn. 2014 Dec;10(4):291-302
pubmed: 24567193
Curr Med Res Opin. 2014 Jul;30(7):1309-16
pubmed: 24502771
Diabetes Care. 2011 Jan;34(1):20-6
pubmed: 20929988
Pharmacoepidemiol Drug Saf. 2004 Sep;13(9):591-8
pubmed: 15362081
N Engl J Med. 2013 Jul 18;369(3):287-8
pubmed: 23863067
Diabetes Educ. 2011 Nov-Dec;37(6):801-12
pubmed: 22021025
J Diabetes. 2016 Jan;8(1):76-85
pubmed: 25565383
J Gen Intern Med. 2003 Aug;18(8):624-33
pubmed: 12911644
Am J Ther. 2014 Jul-Aug;21(4):234-9
pubmed: 23344108
J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):57-64
pubmed: 21335480
Diabetes Care. 2018 May;41(5):929-932
pubmed: 29678864
Health Educ Behav. 2010 Dec;37(6):849-62
pubmed: 21076128
Pharm World Sci. 2006 Apr;28(2):65-72
pubmed: 16791717
Swiss Med Wkly. 2002 Jul 13;132(27-28):379-85
pubmed: 12428192
Expert Opin Pharmacother. 2017 Apr;18(5):503-515
pubmed: 28276972
Diabetes Care. 2017 Nov;40(11):1469-1478
pubmed: 28801475
J Manag Care Spec Pharm. 2017 May;23(5):573-582
pubmed: 28448779
Diabetes Metab. 2003 Feb;29(1):79-81
pubmed: 12629452